- Home
- VTGN
as 11-15-2024 4:00pm EST
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 82.0M | IPO Year: | N/A |
| Target Price: | $15.00 | AVG Volume (30 days): | 261.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.58 - $5.86 | Next Earning Date: | 11-07-2024 |
| Revenue: | $876,000 | Revenue Growth: | 8.16% |
| Revenue Growth (this year): | -32.89% | Revenue Growth (next year): | -40.00% |
Latest VistaGen Therapeutics Inc. News
VTGN Breaking Stock News: Dive into VTGN Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Vistagen to Present at the Stifel 2024 Healthcare Conference
GuruFocus.com
10 days ago
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ...
Zacks
10 days ago
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
Business Wire
10 days ago
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
GuruFocus.com
11 days ago
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect
Business Wire
12 days ago
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
Business Wire
16 days ago
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
Zacks
a month ago
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know
Compare VTGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTGN VistaGen Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.